Biosion, Inc. (“Biosion”), a global R&D stage biotechnology company， announced today the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-060T: anti-siglec-15 antibody and BSI-082: anti-SIRP antibody, at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 8 to 13, 2022.
BSI-060T，a High Affinity, Fully Human Anti-Siglec-15 Antibody as an Alternative Immune Checkpoint Blocker
BSI-060T is a fully human IgG1κ monoclonal antibody, discovered through Biosion’s H³ antibody discovery platform, is able to bind to Siglec-15 protein with high affinity and to potently neutralize Siglec-15-medicated inhibition of CD3-induced T-cell proliferation. BSI-060T exhibits best-in-class biophysical properties and functional characteristics, supporting the initiation of development activities for multiple indications including non-small lung cancer and breast cancer.
BSI-082， a Fully Human Anti-SIRPα Antibody with Both High Specificity and Broad Coverage of SIRPα Variant Populations
BSI-082 is a fully human IgG1/k mAb that binds to SIRPα and blocks the SIRPα/CD47-mediated signaling pathway discovered through Biosion’s H³ antibody discovery platform. BSI-082 exhibits best-in-class biophysical properties, SIRPα specificity, broad SIRPα variant binding and superior functional characteristics, supporting the initiation of development activities for a variety of cancer types.
About AACR Annual Meeting
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
About Biosion, Inc.
Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China. To learn more about Biosion visit www.biosion.com.